Cargando…
Advances in Immunotherapeutics in Pancreatic Ductal Adenocarcinoma
SIMPLE SUMMARY: Pancreatic ductal adenocarcinoma (PDAC) is the most common type of pancreatic cancer, responsible for the majority of cases and ranking seventh as a leading cause of cancer-related deaths. It is difficult to treat because is it often detected at advanced stages, there are no effectiv...
Autores principales: | Chouari, Tarak, La Costa, Francesca Soraya, Merali, Nabeel, Jessel, Maria-Danae, Sivakumar, Shivan, Annels, Nicola, Frampton, Adam E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486452/ https://www.ncbi.nlm.nih.gov/pubmed/37686543 http://dx.doi.org/10.3390/cancers15174265 |
Ejemplares similares
-
A Comprehensive Review of the Current and Future Role of the Microbiome in Pancreatic Ductal Adenocarcinoma
por: Merali, Nabeel, et al.
Publicado: (2022) -
Preclinical mouse models for immunotherapeutic and non-immunotherapeutic drug development for pancreatic ductal adenocarcinoma
por: He, Mengni, et al.
Publicado: (2020) -
The Role of the Multiparametric MRI LiverMultiScan(TM) in the Quantitative Assessment of the Liver and Its Predicted Clinical Applications in Patients Undergoing Major Hepatic Resection for Colorectal Liver Metastasis
por: Chouari, Tarak, et al.
Publicado: (2023) -
Pseudotime dynamics of T cells in pancreatic ductal adenocarcinoma inform distinct functional states within the regulatory and cytotoxic T cells
por: Jainarayanan, Ashwin, et al.
Publicado: (2023) -
Immunophenotypes of pancreatic ductal adenocarcinoma: Meta‐analysis of transcriptional subtypes
por: de Santiago, Ines, et al.
Publicado: (2019)